AstraZeneca terminates oncology sales manager over newsletter comments

Share this article:
AstraZeneca has fired a regional oncology sales director after his advice to reps to “grab a handful” of money when calling on cancer doctors made its way to the blogosphere. Regional sales director Michael Zubillaga, 50, was terminated Friday over comments initially made for the Oncology Newsletter, an internal AstraZeneca publication produced by and for employees at the company’s office in Wayne, PA. In a Q&A section of the newsletter’s winter edition, Zubillaga is quoted stating three sales goals for calling on cancer doctors’ offices for 2007. In goal No. 3 of his advice, Zubillaga said: “I see it like this: There is a big bucket of money sitting in every office. Every time you go in you reach your hand in the bucket and grab a handful. The more times you are in, the more money goes in your pocket. Every time you make a call, you are looking to make more money.” The newsletter was posted on pharmaceutical industry blogs hosted by Peter Rost and Ed Silverman. AstraZeneca said in a statement it, “strongly repudiates the negative comments made in this newsletter. This newsletter was produced outside of AstraZeneca’s required approval and review processes.” An AstraZeneca spokeswoman later told The Philadelphia Inquirer that Zubillaga was fired not for improper conduct, but for his comments, which violated the company’s “robust compliance program that calls for responsible sales and marketing practices and conduct.” Silverman wrote on his blog, pharmalot.com, that Zubillaga’s comments, while crass, might motivate some members of the sales force. “Of course, many docs know that’s what the sales teams think of them,” Silverman wrote. “That’s why some docs hold out for expensive meals, nice trips and good seats to good games, and why others won’t let the rep past reception.” Mike Luby, CEO of prescribing behavior tracking firm TargetRx, said Zubillaga could have accomplished his point by talking about the number of untreated patients, instead of using the “buckets of money” example. “I think what (Zubillaga) did was really stupid and in very bad taste,” Luby told MM&M. “The comments and the sentiment behind his comments are so inconsistent with what you hear from AstraZeneca, as well as the industry in general, that I was glad they moved swiftly and aggressively to send a loud message.”
Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...